nach oben

Medical Oncology

Erschienen in:

01.09.2014 | Original Paper

CISD2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer

verfasst von: Luxin Liu, Meng Xia, Jing Wang, Weijing Zhang, Yanna Zhang, Mian He

Erschienen in: Medical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The CDGSH iron sulfur domain2 (CISD2) is an evolutionarily conserved gene. It functions to control mammalian life span and regulate human breast cancer cells proliferation. However, the characteristics of CISD2 expression and its clinical/prognostic significance are unclear in human tumor. Our study aimed to investigate the expression pattern and clinicopathological significance of CISD2 in patients with early-stage cervical cancer. The mRNA and protein expression levels of CISD2 were analyzed in eight cervical cancer cell lines and eight paired cervical cancer tumors by real-time PCR and Western blotting, respectively. Immunohistochemistry was performed to examine CISD2 protein expression in paraffin-embedded tissues from 149 early-stage cervical cancer patients. Statistical analyses were used to evaluate the clinicopathological significance of CISD2 expression. CISD2 expression was significantly upregulated in cervical cancer cells at both the mRNA and protein levels. Statistical analysis showed a significant correlation of CISD2 expression with the squamous cell carcinoma antigen (P = 0.000), myometrium invasion (P = 0.003), recurrence (P = 0.012), lymphovascular space involvement (P = 0.019) and especially pelvic lymph node metastasis (PLNM; P = 0.000). Patients with higher CISD2 expression had shorter overall survival duration than patients with lower CISD2 expression. Multivariate analysis suggested that CISD2 expression might be an independent prognostic indicator for the survival of patients with early-stage cervical cancer. Our results for the first time suggested that high CISD2 expression was closely correlated with PLNM and poor prognosis in early-stage cervical cancer patients. CISD2 protein might be a novel biomarker for early-stage cervical cancer progression.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef

Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu K. Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101(5):413–7.PubMed

Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, van Themaat EVL, Volders HH, Kok M, ten Hoor KA, Hollema H, de Vries EG, de Bock GH, van der Zee AG, Schuuring E. Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17(6):1317–30.PubMedCrossRef

Berek JS, Hacker NF. Practical gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins; 2004.

Conlan AR, Axelrod HL, Cohen AE, Abresch EC, Zuris J, Yee D, Nechushtai R, Jennings PA, Paddock ML. Crystal structure of Miner1: the redox-active 2Fe-2S protein causative in wolfram syndrome 2. J Mol Biol. 2009;392(1):143–53.PubMedCrossRefPubMedCentral

Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci USA. 2007;104(36):14342–7.PubMedCrossRefPubMedCentral

Chen YF, Kao CH, Chen YT, Wang CH, Wu CY, Tsai CY, Liu FC, Yang CW, Wei YH, Hsu MT, Tsai SF, Tsai TF. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes Dev. 2009;23(10):1183–94.PubMedCrossRefPubMedCentral

Wu CY, Chen YF, Wang CH, Kao CH, Zhuang HW, Chen CC, Chen LK, Kirby R, Wei YH, Tsai SF, Tsai TF. A persistent level of Cisd2 extends healthy lifespan and delays aging in mice. Hum Mol Genet. 2012;21(18):3956–68.PubMedCrossRef

Chen YF, Wu CY, Kirby R, Kao CH, Tsai TF. A role for the CISD2 gene in lifespan control and human disease. Ann N Y Acad Sci. 2010;1201:58–64.PubMedCrossRef

10.

Chen YF, Wu CY, Kirby R, Kao CH, Tsai TF. Cisd2 mediates mitochondrial integrity and life span in mammals. Autophagy. 2009;5(7):1043–5.PubMedCrossRef

11.

Chang NC, Nguyen M, Shore GC. BCL2-CISD2: an ER complex at the nexus of autophagy and calcium homeostasis? Autophagy. 2012;8(5):856–7.PubMedCrossRef

12.

Chang NC, Nguyen M, Germain M, Shore GC. Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1. EMBO J. 2010;29(3):606–18.PubMedCrossRefPubMedCentral

13.

Chang NC, Nguyen M, Bourdon J, Risse PA, Martin J, Danialou G, Rizzuto R, Petrof BJ, Shore GC. Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle. Hum Mol Genet. 2012;21(10):2277–87.PubMedCrossRef

14.

Bu X, Rotter JI. Wolfram syndrome: a mitochondrial mediated disorder? Lancet. 1993;342(8871):598–600.PubMedCrossRef

15.

Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet. 1997;34(10):838–41.PubMedCrossRefPubMedCentral

16.

Puca AA, Daly MJ, Brewster SJ, Matise TC, Barrett J, Shea-Drinkwater M, Kang S, Joyce E, Nicoli J, Benson E, Kunkel LM, Perls T. A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc Natl Acad Sci USA. 2001;98(18):10505–8.PubMedCrossRefPubMedCentral

17.

Sohn YS, Tamir S, Song L, Michaeli D, Matouk I, Conlan AR, Harir Y, Holt SH, Shulaev V, Paddock ML, Hochberg A, Cabanchick IZ, Onuchic JN, Jennings PA, Nechushtai R, Mittler R. NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. PNAS. 2009;110(36):14676–81.CrossRef

18.

Benedet JL, Bender H, Jones H 3rd, Ngan NY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70(2):209–62.PubMedCrossRef

19.

Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ. 2008;178(7):855–62.PubMedCrossRefPubMedCentral

20.

Esajas MD, Duk JM, De Bruijn HWA, Aalders JG, Willemse PHB, Sluiter W, Pras B, ten Hoor K, Hollema H, van der Zee AG. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001;19(19):3960–6.PubMed

21.

Pras E, Willemse PHB, Canrinus AA, De Bruijn HWA, Sluiter WJ, Ten Hoor KA, Aalders JG, Szabo BG, de Vries EG. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Rad Oncol Biol Phys. 2002;52(1):23–32.CrossRef

22.

Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, Aalders JG. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol. 1996;14(1):111–8.PubMed

23.

Lin H, ChangChien CC, Huang EY, Tseng CW, Eng HL, Huang CC. The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer. Acta Obstet Gynecol Scand. 2000;79(2):140–4.PubMedCrossRef

24.

Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 1997;65(2):309–13.PubMedCrossRef

25.

Juang CM, Wang PH, Yen MS, Lai CR, Ng HT, Yuan CC. Application of tumor markers CEA, TPA, andSCC-Ag in patients with low-risk FIGO stage IBand IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;6(1):103–6.CrossRef

26.

Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol. 2000;77(1):164–70.PubMedCrossRef

27.

van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, Water TJ, Berkhof J, van Baal WM, Kenemans P, Verheijen RH. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol Oncol. 2009;112(1):119–25.PubMedCrossRef

28.

Kim Byoung-Gie. Squamous cell carcinoma antigen in cervical cancer and beyond. J Gynecol Oncol. 2013;24(4):291–2.PubMedCrossRefPubMedCentral

29.

Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32.PubMedCrossRef

30.

Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685–98.PubMedCrossRef

31.

Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol. 2013;45(3):745–52.PubMedCrossRef

32.

Joseph SK, Hajnóczky G. IP3 receptors in cell survival and apoptosis: Ca2+ release and beyond. Apoptosis. 2007;12(5):951–68.PubMedCrossRef

33.

Giorgi C, Baldassari F, Bononi A, Bonora M, DeMarchi E, Marchi S, Missiroli S, Patergnani S, Rimessi A, Suski JM, Wieckowski MR, Pinton P. Mitochondrial Ca2+ and apoptosis. Cell Calcium. 2012;52:36–43.PubMedCrossRefPubMedCentral

34.

Giorgi C, Wieckowski MR, Pandolfi PP, Pinton P. Mitochondria associated membranes (MAMs) as critical hubs for apoptosis. Commun Integr Biol. 2011;4(3):334–5.PubMedCrossRefPubMedCentral

35.

Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum–mitochondria connection: one touch, multiple functions. Biochim Biophys Acta. 2013;1837(4):461–9.PubMedCrossRef

36.

Decuypere JP, Monaco G, Bultynck G, Missiaen L, De Smedt H, Parys JB. The IP3 receptor–mitochondria connection in apoptosis and autophagy. Biochim Biophys Acta. 2011;1813(5):1003–13.PubMedCrossRef

37.

Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol. 2008;70:73–91.PubMedCrossRef

38.

Chen R, Valencia R, Zhong F, McColl KS, Roderick HL, Bootman MD, Berridge MJ, Conway SJ, Holmes AB, Mignery GA, Velez P, Distelhorst CW. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol. 2004;166(2):193–203.PubMedCrossRefPubMedCentral

39.

Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. Bax and Bak regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science. 2003;300(5616):135–9.PubMedCrossRef

40.

Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, Parys JB, Leybaert L, Bultynck G. Selective regulation of IP3-receptor-mediated Ca2 + signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ. 2012;19(2):295–309.PubMedCrossRefPubMedCentral

41.

Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-Xl. Nature. 1996;379(6565):554–6.PubMedCrossRef

42.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183–92.PubMedCrossRef

43.

Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, Huang C, Zhou F, Liu M, Wu X, Wang X. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012;5(3):753–60.PubMed

44.

Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I, Leandros E, Michalas S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol. 2000;77(1):129–36.PubMedCrossRef

45.

Cory S, Adams JM. The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev. 2002;2(9):647–56.CrossRef

46.

Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470(2):M55–62.PubMed

47.

Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC, Hsieh YH. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One. 2013;8(8):1–12.

48.

Yan S, Wang Y, Yang Q, Li X, Kong X, Zhang N, Yuan C, Yang N, Kong B. Low-dose radiation-induced epithelial-mesenchymal transition through NF-κB in cervical cancer cells. Int J Oncol. 2013;42(5):1801–6.PubMed

Titel: CISD2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer
verfasst von: Luxin Liu
Meng Xia
Jing Wang
Weijing Zhang
Yanna Zhang
Mian He
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 9/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0183-5

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

CISD2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres

A sub-pathway based method to identify candidate drugs for glioblastomas

Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma

Forced vital capacity predicts long-term survival for curative-resected NSCLC

Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast

Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie